Pfizer Inc.

NYSE:PFE  
54.94
-0.60 (-1.08%)
4:58:11 PM EDT: $54.92 -0.02 (-0.04%)
Products

Pfizer Says U.S. FDA Approved Co’s XELJANZ

Published: 12/14/2021 21:20 GMT
Pfizer Inc. (PFE) - U.S. FDA Approves Pfizer’s Xeljanz® (tofacitinib) for the Treatment of Active Ankylosing Spondylitis.